Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
Obrecht-Sturm D, Schömig L, Mynarek M, Bison B, Schwarz R, Pietsch T, Pfister SM, Sill M, Sturm D, Sahm F, Kortmann RD, Gerber NU, von Bueren AO, Fleischhack G, Schüller U, Nussbaumer G, Benesch M, Rutkowski S.
Obrecht-Sturm D, et al. Among authors: schwarz r.
Neuro Oncol. 2024 Apr 5:noae071. doi: 10.1093/neuonc/noae071. Online ahead of print.
Neuro Oncol. 2024.
PMID: 38578306